HC Wainwright Estimates Surrozen's Q2 Earnings (NASDAQ:SRZN)

Key Points

• HC Wainwright lowered its Q2 2026 EPS estimate for Surrozen to ($1.24) from ($1.03), while still keeping a Buy rating and a $44 price target.
• Surrozen reported a much larger-than-expected Q1 loss of ($11.65) per share, missing the consensus estimate of ($1.09) by $10.56. Revenue came in at $5.0 million, above the $4.0 million forecast.
• Analyst sentiment remains mixed but generally positive, with a Moderate Buy consensus and an average price target of $42. The article also notes recent insider selling by the CEO and a vice president, even as institutional ownership remains high at 66.57%.

Surrozen, Inc. (NASDAQ:SRZN - Free Report) - Analysts at HC Wainwright dropped their Q2 2026 EPS estimates for Surrozen in a report released on Thursday, May 7th. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings of ($1.24) per share for the quarter, down from their previous estimate of ($1.03). HC Wainwright has a "Buy" rating and a $44.00 price target on the stock. The consensus estimate for Surrozen's current full-year earnings is ($7.20) per share. HC Wainwright also issued estimates for Surrozen's Q3 2026 earnings at ($1.19) EPS, Q4 2026 earnings at ($1.14) EPS, FY2026 earnings at ($6.78) EPS, FY2027 earnings at ($4.46) EPS, FY2028 earnings at ($4.70) EPS, FY2029 earnings at ($4.85) EPS and FY2030 earnings at ($4.47) EPS.

Surrozen (NASDAQ:SRZN - Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($11.65) earnings per share for the quarter, missing the consensus estimate of ($1.09) by ($10.56). Surrozen had a negative return on equity of 4,055.04% and a negative net margin of 4,810.50%.The firm had revenue of $5.00 million for the quarter, compared to analysts' expectations of $4.00 million.

Several other research analysts have also recently weighed in on SRZN. Wall Street Zen upgraded shares of Surrozen from a "sell" rating to a "hold" rating in a report on Saturday, March 28th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $40.00 target price on shares of Surrozen in a research note on Tuesday, March 24th. TD Cowen initiated coverage on shares of Surrozen in a research note on Tuesday, April 21st. They issued a "buy" rating on the stock. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Surrozen in a research note on Tuesday, April 21st. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $42.00.

Surrozen Stock Performance

Surrozen stock opened at $28.96 on Monday. Surrozen has a fifty-two week low of $5.90 and a fifty-two week high of $35.00. The stock has a market cap of $332.75 million, a PE ratio of -0.77 and a beta of 0.59. The firm's 50-day simple moving average is $28.50 and its 200 day simple moving average is $22.38.

Institutional Trading of Surrozen

Several hedge funds and other institutional investors have recently modified their holdings of the business. Millennium Management LLC raised its position in shares of Surrozen by 557.1% in the fourth quarter. Millennium Management LLC now owns 721,266 shares of the company's stock valued at $16,301,000 after purchasing an additional 611,497 shares during the period. Braidwell LP raised its position in shares of Surrozen by 235.7% in the fourth quarter. Braidwell LP now owns 470,000 shares of the company's stock valued at $10,622,000 after purchasing an additional 330,000 shares during the period. Spruce Street Capital LP bought a new stake in shares of Surrozen in the fourth quarter valued at approximately $9,764,000. 5AM Venture Management LLC raised its position in shares of Surrozen by 25.0% in the fourth quarter. 5AM Venture Management LLC now owns 387,500 shares of the company's stock valued at $8,758,000 after purchasing an additional 77,500 shares during the period. Finally, Kalehua Capital Management LLC bought a new stake in shares of Surrozen in the fourth quarter valued at approximately $8,705,000. Institutional investors own 66.57% of the company's stock.

Insider Activity at Surrozen

In other Surrozen news, CEO Craig C. Parker sold 4,524 shares of the business's stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $33.33, for a total value of $150,784.92. Following the transaction, the chief executive officer directly owned 16,553 shares in the company, valued at $551,711.49. The trade was a 21.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Yang Li sold 1,584 shares of the business's stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $33.33, for a total transaction of $52,794.72. Following the completion of the transaction, the vice president owned 17,216 shares in the company, valued at approximately $573,809.28. The trade was a 8.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have bought 189,734 shares of company stock valued at $4,677,729 and have sold 8,144 shares valued at $271,440. 31.74% of the stock is currently owned by insiders.

Key Surrozen News

Here are the key news stories impacting Surrozen this week:

• Positive Sentiment: Lifesci Capital raised its estimates for Surrozen’s Q2, Q3, and Q4 2026 earnings, signaling slightly better near-term expectations than before. Source report
• Positive Sentiment: HC Wainwright maintained a Buy rating and a $44 price target on SRZN, suggesting some analysts still see meaningful upside from current levels. Source report
• Neutral Sentiment: A head-to-head comparison article with Rigel Pharmaceuticals was published, but it does not appear to include a direct catalyst for Surrozen’s stock movement. Rigel Pharmaceuticals versus Surrozen Head to Head Comparison
• Negative Sentiment: HC Wainwright cut its FY2026, FY2027, FY2028, FY2029, and FY2030 EPS estimates, pointing to continued expectations for significant losses over the next several years. Source report
• Negative Sentiment: The company’s recent earnings release showed a far larger-than-expected quarterly loss, which likely remains a drag on investor sentiment. Source report

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.